Feed XERS
XE

Xeris Biopharma Holdings, Inc. XERS · NASDAQ

$10.31 +2.38% (+$0.24)

Market cap
$1.74B
Enterprise value
$1.91B
P/E
-
Forward P/E
1,925.3x
PEG
-
P/S
5.2x
P/FCF
31.4x
EV/EBITDA
116.1x
ROIC
12.5%
Bruto marža
83.3%
Neto marža
-5.1%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
10.2x
Beta
0.84
Free float
94.9%

O podjetju

Xeris Biopharma Holdings, Inc. (XERS) is a biotechnology company focused on developing innovative therapeutic treatments for patients with metabolic disorders and endocrine diseases. Their main focus is on developing fixed-dose formulations of therapeutic drugs that can improve patients' quality of life and simplify their treatment regimen. Xeris Biopharma concentrates on areas such as diabetic hypoglycemia, type 1 and 2 diabetes, and adrenal insufficiency. The company is known for its innovative technologies in drug formulation and applications for patients with chronic conditions. Shares of Xeris Biopharma Holdings, Inc. (XERS) may be suitable for investors seeking opportunities in the biotechnology sector with potential for innovative treatments and growth prospects.

Sector

Healthcare

Industry

Biotechnology

CEO

John Shannon

Employees

435

Headquarters

Chicago

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.